Clinical Utility of Virtual Crossmatch Reliability in Living Donor Kidney Transplantation
Nephrology · 2026-11 · 31 (11)
DOI: 10.1111/nep.70309 ↗Abstract
ABSTRACT Donor‐specific antibodies (DSA) are associated with antibody‐mediated rejection (AMR) and graft loss in kidney transplantation. In deceased donor kidney transplantation, virtual crossmatch (VXM) using solid‐phase assays has largely replaced physical crossmatch (PXM). However, comparative data in living donor kidney transplantation (LDKT), particularly for Japanese recipients, remain limited. This study examined the correlation between VXM and PXM and evaluated the incidence of early AMR in Japanese LDKT. We retrospectively analysed 102 LDKT recipients between July 2012 and August 2020, all of whom underwent both VXM and PXM. Patients were stratified into four groups: VXM+/PXM+, VXM+/PXM−, VXM−/PXM+, and VXM−/PXM−. Discordant results were observed in 7% of cases. VXM+/PXM− cases involved low‐titre DSA undetectable by flow cytometric crossmatch (FCXM), whereas all VXM−/PXM+ cases were B‐cell FCXM‐positive in ABO‐incompatible recipients. In ABO‐compatible transplantation, AMR developed in 43% (3/7) of VXM+/PXM+ recipients, 0% (0/1) of VXM+/PXM−, and 2% (1/57) of VXM−/PXM− recipients; no VXM−/PXM+ cases were observed. The VXM+/PXM+ group demonstrated frequent severe AMR, with two cases progressing to chronic active AMR. In contrast, AMR in the VXM−/PXM− group was rare, mild, and successfully managed with steroid pulse therapy alone. These findings indicate that VXM provides reliable immunologic risk stratification in Japanese LDKT and can serve as a practical alternative to PXM without compromising clinical outcomes.
EUVIMED